| Field | Specification |
|---|---|
| Target | |
| Alternative names | Grainyhead-like protein 2 homolog; Brother of mammalian grainyhead; Transcription factor CP2-like 3; GRHL2; BOM; TFCP2L3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human GRHL2 recombinant protein (Position: M1-I625). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets grainyhead-like protein 2 homolog (gene GRHL2) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 71.1 kDa, and the supplier reports an observed band at about 71 kDa.
Grainyhead-like 2 (GRHL2) is an epithelial transcription factor of the Grainyhead family. It maintains epithelial identity by driving genes for cell-cell junctions such as E-cadherin and claudins, is needed for neural tube closure, and suppresses epithelial-mesenchymal transition, so it is studied in development and cancer.
| Target | Grainyhead-like protein 2 homolog (gene GRHL2; UniProt Q6ISB3, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 71.1 kDa |
| Observed MW | 71 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human T-47D cells, human RT4 cells, human Hacat cells, human MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human adenocarcinoma of the right colon tissue, human breast cancer tissue, human placenta tissue, human stomach cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): Caco-2 cells, MCF-7 cells.
Immunogen
Recombinant human GRHL2 fragment (Met1–Ile625), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places grainyhead-like protein 2 homolog in the nucleus and membrane. Tissue expression noted by UniProt (human): Expressed in keratinocytes (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
